1-(2-(4-Aminophenoxy)ethyl)pyrrolidin-2-one | 1099647-54-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(2-(4-Aminophenoxy)ethyl)pyrrolidin-2-one
• 英文别名: 1-[2-(4-aminophenoxy)ethyl]pyrrolidin-2-one
• CAS: 1099647-54-7
• 化学式: C₁₂H₁₆N₂O₂
• mdl: MFCD11652498
• 分子量: 220.27
• InChiKey: SBFXJYCLNBEDDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE ET UTILISATIONS ASSOCIÉES
  申请人：AVILA THERAPEUTICS INC

  公开号：WO2011090760A1

  公开（公告）日：2011-07-28

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物，其药物学上可接受的组成物以及使用它们的方法。
• HETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Singh Juswinder

  公开号：US20100249092A1

  公开（公告）日：2010-09-30

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供化合物及其药学上可接受的组成物，以及使用它们的方法。
• Heteroaryl Compounds and Uses Thereof
  申请人：Singh Juswinder

  公开号：US20100029610A1

  公开（公告）日：2010-02-04

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物、其药学上可接受的组合物以及使用它们的方法。
• AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC SODIUM CHANNELS
  申请人：Hamlyn Richard

  公开号：US20100204224A1

  公开（公告）日：2010-08-12

  Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents; wherein (1) represents (A), (B) or (C); R 1 represents: (a) -L-A or L′-A′ wherein L represents a bond or a C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl moiety, A represents a phenyl, 5- to 10-membered heteroaryl, C 3 -C 6 carbocyclyl or 5- to 10 membered heterocyclyl group, L′ represents a C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl moiety, and A′ represents -Het-A or —X-A wherein Het represents —O—, —S— or NR′, and X represents —CO—, —SO—, SO 2 —, —CO—O—, CO—S, CONR′, —O—CO—, —S—CO— or NR′—CO—, wherein R′ represents hydrogen or C 1 -C 6 alkyl; (b) -L-A-A′ or -L-A-L-A wherein A′ is as defined above, each A is the same or different and is as defined above and each L is the same or different and is as defined above; (c) -A-Z-A wherein Z is -Het-L′, —X-L′, -L′-Het- or L′-X, wherein Het, L′ and X are as defined above and each A is the same or different and is as defined above; (d) -A-Het-Y or -A-X—Y wherein is [L′-Het] n -L′, [L′-Het] n -L′, -[L′-Het] n -A, -L′-B-L′, -L′-B-A or -A-L-A wherein n is from 1 to 4 and B is —X—, —NR′—CO—NR′, —O—CO—NR′— or —NR′—CO—O, and wherein X and L are as defined above, each A is the same or different and is as defined above, each L′ is the same or different and is as defined above, each R′ is the same or different and is as defined above and each Het is the same or different and is as defined above; or (e) -L-CR(A)(A′) or L-CR(A)(L-A) wherein R is hydrogen or C 1 -C 4 alkyl, A′ is as defined above, each L is the same or different and is as defined above and each A is the same or different and is as defined above; R 2 represents -L-A-, L′-A′, -L-A-A′ or L-A-L-A wherein L′ and A′ are as defined above, each L is the same or different and is as defined above and each A is the same or different and is as defined above J represents —NR 3 —, —O— or a direct bond wherein R 3 represent s hydrogen C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl; p is an integer from 1 to 3; q is 1 or 2; and one of E and E′ is —CH 2 — and the other is a direct bond.

  式(I)的化合物及其药学上可接受的盐被发现是SNS钠通道的拮抗剂。它们因此可作为镇痛和神经保护剂使用；其中(1)代表(A)、(B)或(C)；R1代表：(a) -L-A或L'-A'，其中L代表一个键或一个C1-C6烷基，C2-C6烯基或C2-C6炔基基团，A代表一个苯基，5-至10-成员杂芳基，C3-C6环烷基或5-至10-成员杂环基团，L'代表一个C1-C6烷基，C2-C6烯基或C2-C6炔基基团，A'代表-Het-A或-X-A，其中Het代表-O-、-S-或NR'，X代表-CO-、-SO-、SO2-、-CO-O-、CO-S、CONR'、-O-CO-、-S-CO-或NR'-CO-，其中R'代表氢或C1-C6烷基；(b) -L-A-A'或-L-A-L-A，其中A'如上所定义，每个A相同或不同，如上所定义，每个L相同或不同，如上所定义；(c) -A-Z-A，其中Z为-Het-L'、-X-L'、-L'-Het-或L'-X，其中Het、L'和X如上所定义，每个A相同或不同，如上所定义；(d) -A-Het-Y或-A-X-Y，其中是[L'-Het]n-L'、[L'-Het]n-L'、-[L'-Het]n-A、-L'-B-L'、-L'-B-A或-A-L-A，其中n为1至4，B为-X-、-NR'-CO-NR'-、-O-CO-NR'-或-NR'-CO-O，其中X和L如上所定义，每个A相同或不同，如上所定义，每个L'相同或不同，如上所定义，每个R'相同或不同，如上所定义，每个Het相同或不同，如上所定义；或(e) -L-CR(A)(A')或L-CR(A)(L-A)，其中R为氢或C1-C4烷基，A'如上所定义，每个L相同或不同，如上所定义，每个A相同或不同，如上所定义；R2代表-L-A-、L'-A'、-L-A-A'或L-A-L-A，其中L'和A'如上所定义，每个L相同或不同，如上所定义，每个A相同或不同，如上所定义；J代表-NR3-、-O-或直接键，其中R3代表氢、C1-C6烷基、C2-C6烯基或C2-C6炔基；p为1至3的整数；q为1或2；E和E'中的一个为-CH2-，另一个为直接键。
• 2,4-disubstituted pyrimidines useful as kinase inhibitors
  申请人：Celgene CAR LLC

  公开号：US10010548B2

  公开（公告）日：2018-07-03

  The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了可用作激酶抑制剂的 2,4-二取代嘧啶化合物、其药学上可接受的组合物以及使用方法。